EGFR and non-small cell lung carcinoma: The most common secondary mutation is the EGFR T790M mutation.The aberrant activation of tyrosine-protein kinase Met (c-Met) signaling is an EGFR-independent mechanism that confers EGFR TKIs resistance to the NSCLC cells.